US 12,460,179 B2
Lyophilized compositions containing umbilical cord lining stem cells conditioned medium
Rafael Gonzalez, Yorba Linda, CA (US); and Toai Nguyen, Aliso Vijeo, CA (US)
Assigned to RESTEM LLC, Miami, FL (US)
Filed by RESTEM LLC, Miami, FL (US)
Filed on Oct. 14, 2021, as Appl. No. 17/501,775.
Application 17/501,775 is a division of application No. 17/390,574, filed on Jul. 30, 2021.
Application 17/205,910 is a division of application No. 15/248,629, filed on Aug. 26, 2016, abandoned.
Application 17/390,574 is a continuation in part of application No. 17/205,910, filed on Mar. 18, 2021.
Claims priority of provisional application 62/213,537, filed on Sep. 2, 2015.
Prior Publication US 2022/0033772 A1, Feb. 3, 2022
Int. Cl. C12N 5/0775 (2010.01); C12N 5/0735 (2010.01)
CPC C12N 5/0606 (2013.01) [C12N 5/0665 (2013.01); C12N 2501/10 (2013.01); C12N 2501/11 (2013.01); C12N 2501/115 (2013.01); C12N 2501/125 (2013.01); C12N 2501/13 (2013.01); C12N 2501/148 (2013.01); C12N 2501/15 (2013.01); C12N 2501/165 (2013.01); C12N 2501/17 (2013.01); C12N 2501/21 (2013.01); C12N 2501/22 (2013.01); C12N 2501/23 (2013.01); C12N 2501/2303 (2013.01); C12N 2501/2304 (2013.01); C12N 2501/2306 (2013.01); C12N 2501/2307 (2013.01); C12N 2501/2308 (2013.01); C12N 2501/2318 (2013.01); C12N 2501/25 (2013.01); C12N 2502/025 (2013.01); C12N 2533/54 (2013.01); C12N 2533/90 (2013.01)] 6 Claims
OG exemplary drawing
 
1. A lyophilized factor rich composition derived from umbilical cord lining stem cells (ULSCs) conditioned medium comprising:
a) a medium conditioned by ULSCs at a confluence of 80 to 90% without serum, lipids, exogenous growth factors, dexamethasone or antibiotics but including L-alanyl-L-glutamine;
b) a growth factor selected from the group consisting of stem cell factor (SCF), vascular endothelial growth factor (VEGF), nerve growth factor (NGF) and combinations thereof;
c) a cytokine or chemokine selected from the group consisting of interferon gamma (IFN-γ), interleukins (IL) IL-3, IL-4, IL-6, IL-7, IL-8, IL-18, macrophage inflammatory protein-1 beta (MIP1B), monocyte chemoattractant protein-1 (MCP1) and tumor necrosis factor alpha (TNFα) and combinations thereof;
d) a glycosaminoglycan (GAG) selected from the group consisting of hyaluronic acid (HA) and chondroitin sulfate (CS) and combinations thereof; and
e) a collagen selected from the group consisting of collagen I and collagen III.